Last updated: September 15, 2021
Sponsor: RegeneRx Biopharmaceuticals, Inc.
Overall Status: Trial Not Available
Phase
2
Condition
Cardiac Ischemia
Myocardial Ischemia
Cardiovascular Disease
Treatment
N/AClinical Study ID
NCT01311518
RGN-MI-201
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Male and female subjects
- Negative urine pregnancy test at Screening
- An electrocardiogram
- First acute anterior MI
- Baseline angiography
- Onset of chest pain symptoms to initial PCI angioplasty time is 2 to 6 hours
- Written informed consent reviewed and signed by the subject or legally authorizedrepresentatives
Exclusion
Exclusion Criteria:
- Intention to treat subject with thrombolytic therapy following assertion ofThrombolysis In Myocardial Infarction(TIMI) flow 0 or 1 during qualifying angiogram
- History of Myocardial infarctionI or congestive heart failure
- Non-atherosclerotic etiology of acute myocardial infarction
- Cardiogenic shock (systolic blood pressure <90 despite adequate left ventricle fillingpressure or requiring catecholamines) or other hemodynamic instability at baseline
- Further transcatheter or surgical revascularization, e.g., coronary artery bypassgraft planned per baseline angiogram
- Lactating women
- Past or present evidence of malignancy
- Women who have had menarche but have not completed menopause, have not been surgicallysterilized (bilateral tubal ligation or hysterectomy), do not have a partner withdocumented sterility (including vasectomy), or are not using adequate contraception (combined hormonal or double-barrier method of contraception, or sexual abstinence arethe only methods of contraception acceptable for this study)
- Ongoing infectious disease including human immunodeficiency virus (HIV) and hepatitis
- Clinically significant respiratory, renal, metabolic, liver, central nervous system orother comorbid disease, except current cardiovascular disease
Study Design
Study Start date:
July 01, 2019
Estimated Completion Date:
July 31, 2020